You are invited to attend a virtual promotional program by Genentech

Combining the HER2+ Breast Cancer Antibodies You Know in One Fixed-Dose Subcutaneous Injection

Presented by: Eleftherios Mamounas, MD Windermere, FL, Medical Director Comprehensive Breast Program

Virtual Presentation Date and Time:
February 23, 2021 7:00 PM EST

Registration:
Please RSVP by 7:00 PM EST Thursday, 2/18/2021 by emailing your Genentech Host or by going to https://genentechrsvp.com?program_code=CM40349

Genentech Host:
Dean Ballback
(415) 385-0550
ballback.dean@gene.com

PROGRAM OBJECTIVES:
- Provide product overview, including indication, important safety information, dosing, and administration
- Review clinical trial results, including patient, preference data

Please note that this is a promotional educational program; CME credit will not be available.

INDICATIONS

EARLY BREAST CANCER
PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zxxf) is indicated for use in combination with chemotherapy for
- the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for early breast cancer (EBC)
- the adjuvant treatment of adult patients with HER2-positive early breast cancer (EBC) at high risk of recurrence
Select patients for therapy based on an FDA-approved companion diagnostic test.

METASTATIC BREAST CANCER
PHESGO™ is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Select patients for therapy based on an FDA-approved companion diagnostic test.

IMPORTANT SAFETY INFORMATION

BOXED WARNINGS: Cardiomyopathy, Embryo-Fetal Toxicity, and Pulmonary Toxicity

Please see additional Important Safety Information including Black Boxed Warnings on the next page.
IMPORTANT SAFETY INFORMATION (cont)

- PHESGO administration can result in subclinical and clinical cardiac failure. The incidence and severity was highest in patients receiving PHESGO with anthracycline-containing chemotherapy regimens. Evaluate cardiac function prior to and during treatment with PHESGO. Discontinue PHESGO treatment in patients receiving adjuvant therapy and withhold PHESGO in patients with metastatic disease for clinically significant decrease in left ventricular function.

- Exposure to PHESGO can result in embryo-fetal death and birth defects, including oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception.

- PHESGO administration can result in serious and fatal pulmonary toxicity. Discontinue PHESGO for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. Monitor patients until symptoms completely resolve.

CONTRAINDICATIONS
PHESGO is contraindicated in patients with known hypersensitivity to pertuzumab, or trastuzumab, or hyaluronidase, or to any of its excipients.

ADDITIONAL IMPORTANT SAFETY INFORMATION
- Exacerbation of chemotherapy-induced neutropenia
- Hypersensitivity and administration-related reactions (ARRs): Monitor patients for systemic hypersensitivity reactions. Permanently discontinue PHESGO in patients who experience anaphylaxis or severe hypersensitivity reactions.

MOST COMMON ADVERSE REACTIONS

EARLY BREAST CANCER
The most common adverse reactions (>30%) with PHESGO were alopecia, nausea, diarrhea, anemia, and asthenia.

METASTATIC BREAST CANCER (BASED ON IV PERTUZUMAB)
The most common adverse reactions (>30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Prescribing Information for additional Important Safety Information, including BOXED WARNINGS.

Minnesota, Vermont, and Federal Entities (e.g., the Department of Defense and the Department of Veterans Affairs) have restrictions on receiving in-kind benefits (e.g., meals, valet parking) at company-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, Genentech policies may restrict you from consuming any portion of the Genentech-sponsored meal at this program or from receiving any other in-kind benefit from Genentech (e.g., valet parking) in connection with the program.

When you RSVP, please indicate whether you will accept or opt out of Genentech’s in-kind benefits (e.g., meals, valet parking) at the program.

If you choose to opt out, you may either pay for the meal and parking on your own, or not consume anything at the program.

For all program attendees who receive Genentech’s in-kind benefits at this program, Genentech will report the attendee’s name and the value received as required by federal and state disclosure laws (for more information on the federal law, please visit sunshine.gene.com).

The meal cost may vary by event location and be up to $150 per person (exceptions may apply).